These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11026012)

  • 21. [Systemic therapy, pain relief and quality of life of breast cancer patients with bone metastasis].
    Sonoo H; Shimozuma K; Kurebayashi J; Ohta K; Kiyono T
    Gan To Kagaku Ryoho; 1995 Apr; 22 Suppl 1():10-5. PubMed ID: 7747985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy of implantable injection port for advanced breast cancer patients].
    Nakamura S; Itoh M; Ohigashi S; Nishio T; Abe O; Sakurai K
    Gan To Kagaku Ryoho; 1996 Sep; 23(11):1529-32. PubMed ID: 8854798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversible ovarian ablation or chemotherapy: are we ready for quality of life to guide adjuvant treatment decisions in breast cancer?
    Goodwin PJ
    J Clin Oncol; 2003 Dec; 21(24):4474-5. PubMed ID: 14610047
    [No Abstract]   [Full Text] [Related]  

  • 24. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Study on CAF + medroxyprogesterone acetate (MPA) therapy for advanced or recurrent breast cancer--comparison between MPA 600 mg and 1,200 mg. Kyushu CAFT Therapy Study Group (Third Study)].
    Mitsuyama S; Ohno S; Koga T; Takayama T; Yamashita J; Ogawa M; Shirouzu K; Sugimachi K; Nomura Y; Ogawa N
    Gan To Kagaku Ryoho; 1999 Nov; 26(13):2029-36. PubMed ID: 10584567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of locally advanced cancer of the breast].
    Lluch A; Pascual A; Cervantes A; Antón A; Martínez Agulló A; Aviñó J; Alberola V; García-Conde J
    Med Clin (Barc); 1987 May; 89(1):7-10. PubMed ID: 3613742
    [No Abstract]   [Full Text] [Related]  

  • 27. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
    Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The efficacy of combination chemotherapy of 5'-deoxy-5-fluorouridine (5'-DFUR), cyclophosphamide (CPA) and medroxyprogesterone acetate (MPA) for bone metastasis in breast cancer patients].
    Iba T; Kidokoro A; Fukunaga M; Sugiyama K; Aihara N; Suda M
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):973-7. PubMed ID: 11478147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term survival of a patient with primarily chemo-resistant metastatic breast cancer treated with medroxyprogesterone acetate.
    Zaucha R; Sosińska-Mielcarek K; Jassem J
    Breast; 2004 Aug; 13(4):321-4. PubMed ID: 15325667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Adriablastin (doxorubicin) in the combined chemotherapy of patients with disseminated forms of breast cancer].
    Voznyĭ EK; Besova NS; Kurkina TV; Al'tshtuller IuB
    Antibiotiki; 1984 Jun; 29(6):463-8. PubMed ID: 6476811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Criteria for evaluating the efficacy of treatment of breast cancer metastases to the bones].
    Lichinitser MR; Vyshinskaia GV; Gritsaĭ AA; Kondrat'eva AP; Luk'ianchenko AB
    Med Radiol (Mosk); 1986 Feb; 31(2):28-31. PubMed ID: 3951344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [CMF or CAF combination chemotherapy for breast cancer].
    Ota J
    Gan To Kagaku Ryoho; 1996 Dec; 23(14):1886-90. PubMed ID: 8978791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitomycin C + high-dose medroxyprogesterone versus cyclophosphamide+doxorubicin plus fluorouracil as first-line treatment for metastatic breast cancer.
    Falkson CI; Falkson G; Falkson CB; Falkson HC
    Oncology; 1992; 49(6):418-21. PubMed ID: 1465278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
    Green MC; Buzdar AU; Smith T; Ibrahim NK; Valero V; Rosales MF; Cristofanilli M; Booser DJ; Pusztai L; Rivera E; Theriault RL; Carter C; Frye D; Hunt KK; Symmans WF; Strom EA; Sahin AA; Sikov W; Hortobagyi GN
    J Clin Oncol; 2005 Sep; 23(25):5983-92. PubMed ID: 16087943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A long-surviving patient with Stage IV breast cancer with no recurrence after combined therapy of medroxy progesterone acetate (MPA) and intra-arterial infusion chemotherapy].
    Yamada T; Yuyama Y; Okazaki Y
    Gan To Kagaku Ryoho; 2004 Sep; 31(9):1387-9. PubMed ID: 15446562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13 years update in a multicentre randomized trial.
    Focan C; Beauduin M; Salamon E; de Greve J; de Wasch G; Lobelle JP; Majois F; Tagnon A; Tytgat J; van Belle S; Vandervellen R; Vindevoghel A;
    Br J Cancer; 2001 Jul; 85(1):1-8. PubMed ID: 11437394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ineffectiveness of levamisole in prolonging remission or survival of women treated with cyclophosphamide, doxorubicin, and 5-fluorouracil for good-risk metastatic breast carcinoma: a Southeastern Cancer Study Group Trial.
    Carpenter JT; Smalley RV; Raney M; Vogel CL; Weiner RS
    Cancer Treat Rep; 1986 Sep; 70(9):1073-9. PubMed ID: 3527407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Intra-arterial infusion chemotherapy for unresectable or recurrent breast cancer].
    An M; Matsumoto Y; Kishi T; Terakado H; Ikawa M; Hamada E; Watanabe Y; Nakasato S; Murata M; Takaki S; Miura T; Idezuki Y; Kobayashi M
    Gan To Kagaku Ryoho; 1998 Jul; 25(9):1330-2. PubMed ID: 9703820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study.
    Bottomley A; Biganzoli L; Cufer T; Coleman RE; Coens C; Efficace F; Calvert HA; Gamucci T; Twelves C; Fargeot P; Piccart M;
    J Clin Oncol; 2004 Jul; 22(13):2576-86. PubMed ID: 15226325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.